68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic prostate cancer patients

Anouk C. de Jong, MD1,2*, Minke Smits, MD3*, Job van Riet, BSc1,4, prof. Jurgen J. Fütterer, MD, PhD5, Tessa Brabander, MD, PhD2, Paul Hamberg, MD, PhD6, Inge M. van Oort, MD PhD7, prof. Ronald de Wit, MD, PhD1, Martijn P. Lolkema, MD, PhD1, Niven Mehra, MD, PhD3, Marcel Segbers, MSc2#, Astrid A.M. van der Veldt, MD, PhD1,2#

*Shared first author, #Shared last author

1 Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; 2 Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands; 3 Department of Medical Oncology, Radboud UMC, Nijmegen, The Netherlands; 4 Cancer Computational Biology Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; 5 Department of Radiology and Nuclear Medicine, Radboud UMC, Nijmegen, The Netherlands; 6 Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands; 7 Department of Urology, Radboud UMC, Nijmegen, The Netherlands.

Corresponding author: A.A.M. van der Veldt, Department of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Tel: +31 (0)10 704 17 54. Fax: +31 (0)10 704 10 03. E-mail address: a.vanderveldt@erasusmc.nl
First authors:

1. A.C. de Jong, MD, PhD candidate, Department of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Tel: +31 (0)10 704 4375. Fax: +31 (0)10 704 10 03. E-mail address: a.c.dejong@erasmusmc.nl

2. M. Smits, MD, PhD candidate, Department of Medical Oncology, Radboud UMC, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. Tel: +31 (0)24 361 03 53. E-mail address: m.smits@radboudumc.nl

This work was presented at the European Society for Medical Oncology 2019 in Barcelona and selected as winner of Best Poster Award at ESMO 2019.

Word count abstract: 297

Word count total manuscript: 5583

Financial support is not applicable. For brevity, the disclaimer is listed once at the end of the manuscript.

Short running title: $^{68}$Ga-PSMA guided bone biopsies
ABSTRACT

For individual treatment decisions in patients with metastatic prostate cancer (mPC), molecular diagnostics are increasingly used. Bone metastases are frequently the only source for obtaining metastatic tumor tissue. However, the success rate of computed tomography (CT)-guided bone biopsies for molecular analyses in mPC patients is only ~40%. Positron emission tomography (PET) using Gallium-68 prostate specific membrane antigen ($^{68}$Ga-PSMA) is a promising tool to improve the harvest rate of bone biopsies for molecular analyses. Aim of this study was to determine the success rate of $^{68}$Ga-PSMA guided bone biopsies for molecular diagnostics in mPC patients.

Methods: Within a prospective multicenter whole-genome sequencing trial (NCT01855477), 69 mPC patients underwent $^{68}$Ga-PSMA PET/CT prior to bone biopsy. Primary endpoint was success rate (tumor percentage ≥30%) of $^{68}$Ga-PSMA guided bone biopsies. At biopsy sites, $^{68}$Ga-PSMA uptake was quantified using rigid body image registration of $^{68}$Ga-PSMA PET/CT and interventional CT. Actionable somatic alterations were identified. Results: Success rate of $^{68}$Ga-PSMA guided biopsies for molecular analyses was 70%. At biopsy sites categorized as positive, inconclusive, or negative for $^{68}$Ga-PSMA uptake, 70%, 64%, and 36% of biopsies were tumor positive (≥30%), respectively (p=0.0610). In tumor positive biopsies, $^{68}$Ga-PSMA uptake was significantly higher (p=0.008), whereas radiodensity was significantly lower (p=0.006). With an area under the curve of 0.84 and 0.70, both $^{68}$Ga-PSMA uptake (maximum standardized uptake value) and radiodensity (mean Hounsfield Units) were strong predictors for a positive biopsy. Actionable somatic alterations were detected in 73% of the sequenced biopsies. Conclusion: In patients with mPC, $^{68}$Ga-PSMA PET/CT improves the success rate of CT-guided bone biopsies for molecular analyses, thereby identifying actionable somatic alterations in more patients. Therefore, $^{68}$Ga-
PSMA PET/CT may be considered for guidance of bone biopsies in both clinical practice and clinical trials.

Keywords: bone biopsy, $^{68}$Ga-PSMA-PET, molecular diagnostics, whole genome sequencing, prostate cancer.
**INTRODUCTION**

With more than 350,000 men dying of prostate cancer in 2018, prostate cancer is not only one of the most common malignancies in men, but also the fifth leading cause of cancer-related death worldwide\(^1\). To improve treatment planning for individual patients with metastatic prostate cancer (mPC), molecular analyses are increasingly used to predict treatment response, guide clinical decision making and identify additional targets for targeted therapy\(^2-4\). Due to tumor evolution and genetic adaption following castration resistance and subsequent treatment resistance, tumor DNA for molecular analyses is preferably obtained from a biopsy of a metastatic lesion. As bone-only and bone predominant disease are most frequently reported in patients with mPC, bone metastases are usually the only source for molecular analyses\(^5-6\).

In men with mPC, 67-77% of bone biopsies have sufficient quality for diagnostic histopathological examination\(^7-9\). However, molecular analyses on CT-guided bone biopsies from prostate cancer are less feasible, as the success rate is only 39-44% and 36.5% for RNA analysis and whole exome sequencing, respectively\(^7, 8, 10\). This poor success rate of bone biopsies might be due to the predominantly osteoblastic character of these metastases. As bone metastases of prostate cancer have a dense sclerotic matrix and decreased tumor cellularity, these lesions are difficult to distinguish from non-malignant osteosclerosis on CT\(^11\).

In clinical practice, most bone biopsies are guided by computed tomography (CT). Since the yield of CT-guided bone biopsies for molecular analyses is rather low, the use of molecular diagnostics for personalized treatment in prostate cancer patients is limited. To improve the yield of bone biopsies in mPC patients, biopsies could be obtained from bone metastases, which express prostate specific membrane antigen (PSMA). In the apical region of normal prostate cells, PSMA shows physiological
expression, whereas it is usually 100-1000x overexpressed in prostate cancer cells\(^{12}\). To visualize and quantify PSMA expression \textit{in vivo}, positron emission tomography (PET) using Gallium-68 PSMA \((^{68}\text{Ga-PSMA})\) can be performed. Nowadays, \(^{68}\text{Ga-PSMA}\) PET/computed tomography (CT) is increasingly used in the setting of biochemical recurrence, as it has a high sensitivity and specificity for early detection of prostate cancer\(^{13}\). Recently, fused images of \(^{68}\text{Ga-PSMA}\) PET/CT and diffusion weighted MRI, in combination with cone-beam CT guidance, have been applied to guide bone biopsies in patients with prostate cancer. Though in a small number of patients (N=10), this pilot study showed a success rate of 80\%\(^{14}\). Therefore, \(^{68}\text{Ga-PSMA}\) PET/CT is a promising technique to increase the success rate of bone biopsies for molecular analyses in prostate cancer patients.

Within a prospective multicenter whole-genome sequencing (WGS) trial, we determined the success rate of \(^{68}\text{Ga-PSMA}\) guided bone biopsies for molecular diagnostics in metastatic prostate cancer patients. In addition, we evaluated the potential impact of these molecular analyses on clinical decision making in mPC patients.

**MATERIALS AND METHODS**

**Design**

In this comprehensive PET study, mPC patients, who had a \(^{68}\text{Ga-PSMA}\) guided bone biopsy within the prospective multicenter nationwide CPCT-02 study (NCT01855477), were included\(^{15}\). CPCT-02 aims to improve selection of patients for experimental therapy by WGS of tumor DNA, which is obtained by image-guided biopsies. For the current study, informed consent was obtained within CPCT-02, and additional approval was provided by the institutional review boards of two academic
institutes in the Netherlands: Erasmus Medical Center in Rotterdam (EMC) and Radboud University Medical Center in Nijmegen (RUMC).

Patients

Between December 2014 and July 2018, all mPC patients, who underwent $^{68}$Ga-PSMA PET/CT within 12 weeks prior to a completed bone biopsy procedure within CPCT-02, were included. Full in- and exclusion criteria of CPCT-02 were described previously (15). Tumor tissue was obtained from a metastatic lesion to fully capture the genomic tumor evolution. Patients could be included at multiple time points in their treatment course, resulting in repeated biopsies for some patients. Biopsies were always obtained prior to the start of a new systemic treatment. Clinical data were collected in an electronic case report form (ALEA Clinical).

Primary and Secondary Endpoints

Primary endpoint was the success rate of $^{68}$Ga-PSMA guided bone biopsies in patients with mPC, with success defined as $\geq 30\%$ tumor cells in at least one biopsy core (i.e. the minimal amount of tissue required for DNA isolation for WGS), as assessed by a dedicated pathologist. Exploratory endpoints included the correlation between biopsy success and imaging (standardized uptake value [SUV] and Hounsfield Units [HU]) and laboratory variables (haemoglobin [Hb], alkaline phosphatase [ALP], prostate specific antigen [PSA], and lactate dehydrogenase [LDH]). In addition, the potential impact of molecular analyses on clinical decision making was evaluated.
Image Acquisition

Prior to the biopsy procedure, $^{68}$Ga-PSMA PET/CT was performed to identify a biopsy site with high $^{68}$Ga-PSMA uptake. During the procedure, biopsies were performed with or without CT, or ultrasound guidance, based on the interventional radiologist's decision.

$^{68}$Ga-PSMA PET and Low Dose CT. On-site, PSMA-HBED-CC was labelled with $^{68}$Ga and administered intravenously with a mean (± SD) single bolus of 133 ± 35 MBq $^{68}$Ga-PSMA-HBED-CC. At 60 minutes post injection, images were acquired from head to mid-thigh on a Biograph mCT PET/CT scanner (Siemens Healthineers, Erlangen, Germany). A low-dose CT was acquired with 120kV and 40 reference mAs (EMC) or 50 reference mAs (RUMC). All PET data were obtained during 3 minutes per bed position, except for images with 4 minutes per bed position for patients with weight >70 kg in EMC. For quantitative analyses of $^{68}$Ga-PSMA uptake, data were reconstructed according to Evaluation and Report Language (16).

Interventional CT. Prior to CT acquisition for CT-guided biopsy, the field of view was determined by acquiring an overview image. Next, subsequent CT scans with a smaller field of view were acquired to visualize the biopsy needle until the biopsy site was reached.

Biopsy Procedure

Bone biopsies were performed according to local institutional guidelines. The biopsy site was selected by the interventional radiologist based on clinical judgement, safety, and prior imaging including $^{68}$Ga-PSMA PET/CT.

Image Analyses
*Rigid Body Image Registration.* In order to evaluate whether biopsies were accurately obtained from a $^{68}$Ga-PSMA positive lesion, co-registration of $^{68}$Ga-PSMA PET/CT and the interventional CT was retrospectively performed using rigid body image registration. This analysis, which was performed with the Elastix Toolbox\((17, 18)\), enables measurement of $^{68}$Ga-PSMA uptake at the exact position of the biopsy site. When the image quality of $^{68}$Ga-PSMA PET, low-dose CT and interventional CT was sufficient for rigid body image registration, patients were included for this exploratory analysis. Rigid body image registration merges $^{68}$Ga-PSMA PET/CT and the interventional CT within two steps. To exclude soft tissues in both image registration steps, bone masks were obtained by applying a region growing algorithm that included CT voxels $>150$ HU. In the first co-registration step, patient motion on interventional CT is corrected by co-registration of the overview image and the image acquired during biopsy. Next, the overview image of the interventional CT was co-registered with the low-dose CT of the $^{68}$Ga-PSMA PET/CT image. Combining rotation calculations from both image registration steps with interventional CT enabled fusion of $^{68}$Ga-PSMA PET with the interventional CT, thereby visualizing the biopsy needle.

$^{68}$Ga-PSMA Uptake and Radiodensity at Biopsy Site. An experienced nuclear medicine physician (T.B.), who was blinded for the biopsy results, determined visually whether the biopsy was accurately taken from a $^{68}$Ga-PSMA positive lesion, using a three-point scale categorized as hit, borderline or miss. Besides these qualitative analyses, quantitative analyses consisted of SUV and HU measurements. To measure $^{68}$Ga-PSMA uptake (SUV) and radiodensity (HU) at the exact biopsy location, a cylindrical volume of interest (VOI) with a length of 2 cm and a diameter of 1 cm was drawn at the site of the biopsy as visualized on rigid body co-registration images of $^{68}$Ga-PSMA PET and interventional CT. VOIs were defined in Python using in-house
developed scripts, based on SimpleITK framework for medical imaging (19). The maximum and mean SUV of $^{68}$Ga-PSMA uptake were calculated using the injected radioactivity, body weight and the amount of radioactivity within a VOI. To assess radiodensity in bone metastases, HUs were determined on CT images. For CT measurements, if necessary, VOIs were minimally moved or reduced in size to avoid overlap with cortical bone.

**Molecular Analyses**

Alterations in genes described in OncoKB, a precision oncology knowledge base, were extracted from the genomic data of all successfully sequenced biopsies and categorized as level 1, 2, 3, or 4 alterations, based on available (clinical) evidence (20). In addition, PTEN deletions were extracted as these might also be actionable with AKT-inhibitors (2). Genomic analyses are described in detail in the Supplementary (20-27).

**Statistical Analyses**

Depending on normality distribution, the unpaired t-test or Mann-Whitney U test was used to test for differences between clinical variables (age, Gleason score, haemoglobin, ALP, LDH, and PSA), imaging variables ($\text{HU}_{\text{mean}}$, $\text{HU}_{\text{max}}$, $\text{SUV}_{\text{mean}}$, and $\text{SUV}_{\text{max}}$), and primary outcome of biopsy ($\geq30\%$ tumor). To test for differences between the summed Gleason score ($<8$ and $\geq8$) and primary outcome, a Chi-square test was used. The three $^{68}$Ga-PSMA uptake categories (hit, borderline, miss) were compared for tumor positivity ($\geq30\%$ tumor) using the Chi-square for trend test. For SUV at the biopsy location, the three biopsy outcome groups were compared using the Kruskal-Wallis test in combination with Dunn’s multiple comparisons test. Univariate and multivariate regression analyses were performed to evaluate relations between
variables and primary outcome. For these analyses all non-normal distributed variables were log-transformed prior to testing. Since normal distribution was not reached for LDH by log-transformation, LDH was categorized in normal LDH (<250) and elevated (≥250) and a Chi-square test was used to test for an association with biopsy outcome. Univariate logistic regression analysis tested for any association between continuous variables and primary outcome. Subsequently, significantly associated variables were selected for multivariate logistic regression analysis. Due to the relatively small sample size, the most significant variables of HU (mean or max) and SUV (mean or max) were selected for multivariate testing. No correction was set for multiplicity of secondary endpoints. Odds for a positive biopsy were calculated by logistic regression for SUV and HU. For the area under the curve and receiver operating characteristic curve, the logarithm of odds was calculated. Receiver operating characteristic curves were calculated for $\text{HU}_{\text{mean}}$ and $\text{SUV}_{\text{max}}$. All statistical tests were performed two-sided. A $p$-value of ≤0.05 was considered statistically significant.

RESULTS

Biopsy Selection

Between December 2014 and June 2018, 115 bone biopsies from 103 patients with mPC were obtained within CPCT-02 in EMC and RUMC. Prior to 71 biopsies (62%), $^{68}$Ga-PSMA PET/CT was performed to identify bone metastases, while 44 biopsies (38%) within CPCT-02 were preceded by other imaging modalities. Two out of 71 $^{68}$Ga-PSMA guided biopsies (3%) were not eligible because of a failed biopsy procedure and >12 weeks between imaging and biopsy. In total, 69 $^{68}$Ga-PSMA guided biopsies, from 60 individual patients, were eligible for primary analysis to determine the success rate of $^{68}$Ga-PSMA guided bone biopsies (Fig. 1). Seven patients underwent two $^{68}$Ga-
PSMA guided bone biopsies. One patient underwent three $^{68}$Ga-PSMA guided bone biopsies. Median time between $^{68}$Ga-PSMA PET/CT and the biopsy procedure was nine days (interquartile range 3-22).

**Clinical Characteristics and Success Rate of $^{68}$Ga-PSMA Guided Biopsies**

The clinical characteristics of patients and biopsies are described in Table 1. Biopsies were primarily performed in the castration resistant setting (97%, N=67) and most commonly obtained from the pelvis (N=57, 83%). During the procedure, biopsies were performed unguided (N=5, 7%), or guided by ultrasound (N=1, 1%), or CT (N=63, 91%), based on the interventional radiologist’s decision. During one biopsy procedure (1%), excessive bleeding, which was directly controlled by manual pressure, occurred.

Based on tumor percentage ($\geq 30\%$) in at least one core, 48 out of 69 (70%) $^{68}$Ga-PSMA guided biopsies (44 out of 60 individual patients (73%)) were eligible for molecular analyses. No significant differences were found in age ($p=0.42$), Gleason score ($p=0.46$) and baseline laboratory findings (Hb $p=0.54$, PSA $p=0.36$, ALP $p=0.56$) between biopsies with tumor percentage $<30\%$ and $\geq 30\%$, although elevated LDH levels were seen with borderline significance in the group with a successful biopsy ($p=0.05$). In the univariate logistic regression analysis, none of these variables were associated with biopsy outcome (data not shown). The success rate of biopsies obtained from pelvis (N=57, 83%), spine (N=6, 9%), and other locations (N=6, 9%) was 65%, 100% and 83%, respectively.

**$^{68}$Ga-PSMA Uptake and Radiodensity at Biopsy Site**

To evaluate whether biopsies were accurately obtained from lesions with high $^{68}$Ga-PSMA uptake, $^{68}$Ga-PSMA PET/CT was co-registered with interventional CT (Figs. 2a-
d) for qualitative and quantitative analyses (Fig.1). For 55 biopsies, rigid body image registration could be performed adequately (Fig. 1). Based on the rigid body image registrations, 33 biopsies were categorized as hit, 11 biopsies as borderline, and 11 biopsies as miss (Fig. 3a). As expected, biopsy sites categorized as hit had higher SUV\text{\textsubscript{max}} and SUV\text{\textsubscript{mean}} compared with biopsy sites categorized as miss (p<0.001 for both) (Figs. 3b-c). Subsequently, the correlation between 68\textsuperscript{Ga}-PSMA uptake and biopsy outcome was evaluated. At biopsy sites categorized as hit, borderline or miss for 68\textsuperscript{Ga}-PSMA uptake, 70\%, 64\%, and 36\% of biopsies were tumor positive (≥30\%), respectively (p=0.0610, Fig. 3a).

At biopsy sites with tumor percentage ≥30\%, median 68\textsuperscript{Ga}-PSMA uptake was significantly higher (SUV\text{\textsubscript{max}} 20.9, inter quartile range [IQR] 10.0-32.1; SUV\text{\textsubscript{mean}} 10.3, IQR 3.4-18.7), whereas median 68\textsuperscript{Ga}-PSMA uptake was lower at biopsy sites with tumor percentage <30\% (SUV\text{\textsubscript{max}} 6.7, IQR 3.7-14.2; SUV\text{\textsubscript{mean}} 3.4, IQR, 1.8-9.1; p=0.0021 and p=0.0123, respectively) (Figs. 4a-b). In contrast, median radiodensity on CT was significantly lower at biopsy sites with tumor percentage ≥30\% (HU\text{\textsubscript{max}} 786, IQR 600-977; HU\text{\textsubscript{mean}} 294, IQR 184-473) as compared to biopsy sites with tumor percentage <30\% (HU\text{\textsubscript{max}} 1019, IQR 780-1132; HU\text{\textsubscript{mean}} 524, IQR 296-738; p=0.0266 and p=0.0064, respectively) (Figs. 4c-d). In univariate logistic regression analysis, SUV and HU values were also significantly associated with biopsy outcome (SUV\text{\textsubscript{max}} p=0.008, SUV\text{\textsubscript{mean}} p=0.016, HU\text{\textsubscript{mean}} p= 0.006, and HU\text{\textsubscript{max}} p=0.037) (Supplemental Table 1a). After stepwise multivariate analysis, HU\text{\textsubscript{mean}} and SUV\text{\textsubscript{max}} resulted in an odds ratio of 0.995 (95\%CI 0.992-0.998, p=0.003) and 11.737 (95\%CI 2.258-60.996, p=0.003), respectively (Supplemental Table 1b). Receiver operating characteristic curves of HU\text{\textsubscript{mean}} and SUV\text{\textsubscript{max}} for successful biopsies had an area under the curve of 0.70 and 0.84, respectively (Supplemental Fig. 1).
Clinical Impact of $^{68}$Ga-PSMA Guided Bone Biopsies for Molecular Analyses

Forty out of 48 positive biopsies (83%) were successfully used for WGS (Fig. 1). Median in silico tumor purity of the successfully sequenced samples was 55% (range 17-94%) (Supplemental Fig. 2)(20-27). In total, 53 actionable somatic alterations were detected in 73% (N=29) of the successfully sequenced biopsies (Fig. 5). Forty-one actionable somatic alterations, detected in 21 biopsies, were described in the OncoKB database as level 1 (n=9, 22%), level 2 (n=4, 10%), level 3 (n=13, 32%), and level 4 (n=15, 37%)(20). Twelve biopsies (30%) contained a deep PTEN deletion, which is not (yet) included in the OncoKB database, but might be actionable with AKT-inhibitors(2).

The genomic landscape of metastatic castration resistant prostate cancer, including this subset of biopsies, has been described in detail by Van Dessel et al.(22).

DISCUSSION

In this comprehensive PET study, we show that $^{68}$Ga-PSMA guided bone biopsies provide sufficient quality for molecular analyses in 70% of the biopsies. Our findings indicate that $^{68}$Ga-PSMA guided bone biopsies are more successful than bone biopsies with CT-guidance only, that have a reported success rate for molecular analysis of only 36.5-44% in patients with mPC (7, 8, 10). With 70% of the biopsies being successful for molecular analyses, the success rate approximates the overall success rate of 76.5% for 3655 biopsies within the CPCT-02 study, which mainly included non-skeletal biopsies(21).

For objective analyses of the success rate of $^{68}$Ga-PSMA guided bone biopsies, we applied rigid body image registration, which confirmed that the majority of biopsies was accurately obtained from a lesion with high $^{68}$Ga-PSMA uptake. In addition, there was
a trend towards a higher percentage of tumor positive biopsies in the hit group. For biopsies with a tumor percentage of ≥30%, $^{68}$Ga-PSMA uptake was significantly higher than for biopsies with a tumor percentage of <30%. In contrast, HU values on CT were lower for biopsies with a tumor percentage of ≥30% than for biopsies with a tumor percentage of <30%. The higher success rate of biopsies from bone lesions with lower HU values has also been reported by two other studies (7,8), indicating that osteosclerotic lesions with high HU values contain less viable tumor cells. With an area under the curve of 0.84 and 0.70, both SUV$_{max}$ and HU$_{mean}$ were strong predictors for a positive biopsy. In the absence of $^{68}$Ga-PSMA PET/CT, it might therefore be advisable to obtain biopsies from less sclerotic lesions with lower HU values.

The high frequency of actionable alterations, found in this study, emphasizes the medical need for a high success rate of bone biopsies. Within the CPCT-02 trial, potentially actionable alterations, identified by WGS of the tumor biopsy, were shared with the patient to enable targeted treatment in, for example, the Drug Rediscovery Protocol (NCT02925234). According to this protocol, patients are treated with approved, off-label targeted agents based on the molecular characteristics of the tumor. First results are promising with clinical benefit for multiple treatment cohorts (28). As $^{68}$Ga-PSMA PET is increasingly and widely available in current clinical practice, it can be easily implemented to improve the success rate of bone biopsies. By optimizing the first step of the pipeline for molecular diagnostics, $^{68}$Ga-PSMA PET significantly contributes to improved genomic characterization of mPC.

Although the current study shows a high success rate, there are a few limitations of $^{68}$Ga-PSMA guided bone biopsies for molecular diagnostics. First, tumor heterogeneity might be better reflected by molecular analyses of liquid biopsies than by WGS of tumor tissue from a single lesion. However, techniques for detailed molecular analyses
of liquid biopsies are still under development, while WGS of tissue biopsies is currently more feasible. Second, PSMA expression has high inter- and intra-patient heterogeneity (29). High PSMA expression is associated with defective DNA damage repair and PTEN loss, whereas patients with low $^{68}$Ga-PSMA expression have poor survival (29-31). Since bone biopsies in this study were not obtained from metastases with low $^{68}$Ga-PSMA uptake, these sites are underrepresented in the current study.

In addition, there were some notable results. First, four biopsies that were scored as miss ($^{68}$Ga-PSMA negative) did contain ≥30% tumor cells (false negative). As these biopsies were all close to a $^{68}$Ga-PSMA positive lesion, these false negative results may be due to patients' movements and/or different spatial resolution between scans. Although the majority of biopsies was accurately obtained from lesions with high $^{68}$Ga-PSMA uptake, guidance might be further optimized by real-time visualization of $^{68}$Ga-PSMA uptake, though this is technically and logistically more challenging.

Second, in five biopsies, which were all obtained from spine or ribs, image registration failed. This image registration failure at non-pelvic sites may be explained by the rigid body algorithm, which relies on the assumption that the spine and rib cage are rigid bodies. As the rigid body algorithm was only applied for image analyses in this study, this limitation will not impact the feasibility of $^{68}$Ga-PSMA guided biopsies from non-pelvic sites in clinical practice.

CONCLUSION

In conclusion, $^{68}$Ga-PSMA guided bone biopsies have a 70% success rate for molecular analyses in mPC patients, indicating that $^{68}$Ga-PSMA PET/CT has added value to increase the success rate of CT-guided bone biopsies. In successful $^{68}$Ga-PSMA guided biopsies, whole genome sequencing identified numerous targetable
mutations, emphasizing the potential clinical impact of $^{68}$Ga-PSMA guided bone biopsies in mPC patients.

**DISCLOSURE**

Funding was not applicable. A.C. de Jong, M. Smits, J. van Riet, T. Brabander, P. Hamberg and M. Segbers declare that they have no competing interests. J. Fütterer received speaker fees from Astellas and Siemens, and received institutional research support from Siemens. I.M. van Oort received speaker fees from Astellas, Janssen, Bayer, MDxHealth and Sanofi. R. de Wit received advisory fees from Sanofi, Merck, Bayer, Roche, Janssen and Clovis, speaker fees from Sanofi and Merck and institutional research grants from Sanofi and Bayer. M. Lolkema received institutional research funding from Johnson & Johnson and Astellas. N. Mehra played an advisory role (both institutional as personal) for Roche, MSD, Bayer, Astellas and Janssen, received research support (institutional) from Astellas, Janssen, Pfizer, Roche and Sanofi, Genzyme and travel support from Astellas, MSD. A.A.M. van der Veldt is a member of the advisory board of BMS, MSD, Roche, Novartis, Pierre Fabre, Pfizer, Sanofi and Ipsen. No other potential conflicts of interest relevant to this article exist.

**ACKNOWLEDGEMENTS**

We thank, S. Klein and A. Moelker for their contribution to the rigid body image registration analysis, M. Simons for help with the molecular analyses, A. Rieborn and W. Onstenk for help with collecting data, and E. Oomen - de Hoop for statistical advice.

**KEY POINTS**
QUESTION: What is the success rate of $^{68}\text{Ga}$-PSMA guided bone biopsies for molecular analyses in metastatic prostate cancer patients?

PERTINENT FINDINGS: Within a prospective multicenter whole-genome sequencing trial (NCT01855477), 69 metastatic prostate cancer patients underwent $^{68}\text{Ga}$-PSMA PET/CT prior to bone biopsy. The success rate of $^{68}\text{Ga}$-PSMA guided bone biopsies for molecular analyses was 70%.

IMPLICATIONS FOR PATIENT CARE: In patients with metastatic prostate cancer, $^{68}\text{Ga}$-PSMA PET/CT improves the success rate of CT-guided bone biopsies for molecular analyses, thereby identifying actionable somatic alterations in more patients.

REFERENCES


Figures and figure legends

**Figure 1** Flowchart of included $^{68}$Ga-PSMA guided bone biopsies for primary and secondary analyses of the current PET study within CPCT-02. WGS: whole genome sequencing, SUV: standardized uptake value, HU: Hounsfield Units.
Figure 2 Rigid body image registration of $^{68}$Ga-PSMA PET/CT and interventional CT visualizes biopsy needle on $^{68}$Ga-PSMA PET and enables measurement of $^{68}$Ga-PSMA uptake and radiodensity at biopsy site. A) $^{68}$Ga-PSMA PET/CT, prior to the biopsy. B) CT, acquired during the biopsy procedure. C) Co-registration of $^{68}$Ga-PSMA PET/CT and interventional CT. D) Visualization of biopsy needle on $^{68}$Ga-PSMA PET/CT.
Figure 3: $^{68}$Ga-PSMA uptake at biopsy sites

A) Biopsy sites were categorized as hit ($^{68}$Ga-PSMA positive), borderline or miss ($^{68}$Ga-PSMA negative) by a blinded nuclear medicine physician and correlated to tumor percentage ($\geq 30\%$ vs $<30\%$; $N=55$ biopsies). Chi-square for trend test.

B) SUV$_{\text{max}}$ at biopsy site, categorized by $^{68}$Ga-PSMA uptake score ($N=55$ biopsies). Kruskal-Wallis in combination with Dunn’s multiple comparisons test.

C) SUV$_{\text{mean}}$ at biopsy site, categorized by $^{68}$Ga-PSMA uptake score ($N=55$ biopsies). Kruskal-Wallis in combination with Dunn’s multiple comparisons test.
Figure 4 $^{68}$Ga-PSMA uptake (SUV) and radiodensity (HU) in biopsies with tumor percentage $\geq 30\%$ and $< 30\%$. A) $\text{SUV}_{\text{max}}$, B) $\text{SUV}_{\text{mean}}$, C) $\text{HU}_{\text{max}}$, D) $\text{HU}_{\text{mean}}$. N=55 biopsies. Mann Whitney test was performed for all parameters. SUV: standardized uptake values, HU: Hounsfield Units.
Figure 5 Actionable somatic alterations, detected by whole genome sequencing, in $^{68}$Ga-PSMA PET guided bone biopsies from metastatic prostate cancer patients. Genes with actionable somatic alterations are categorized by level of evidence for targeted therapy as described in the OncoKB database. Evidence for both prostate cancer and other malignancies was combined within one category. Level 1: FDA-recognized biomarker predictive of response to an FDA-approved drug. Level 2: Standard care biomarker predictive of response to an FDA-approved drug. Level 3: Compelling clinical evidence supports the biomarker as being predictive of response to a drug. Level 4: Compelling biological evidence supports the biomarker as being predictive of response to a drug. For every altered gene, an example of a targeted therapy suitable for the specific alteration was described. WGS: whole genome sequencing, OC: ovarian cancer, BC: breast cancer, AML: acute myeloid leukemia, CNS: central nervous system cancer, LS: liposarcoma, NSCLC: non-small cell lung cancer, LSCC: lung squamous cell carcinoma, Mel: melanoma, Gl: glioma, BLC: bladder cancer.
Table 1 Clinical characteristics at time of biopsy

<table>
<thead>
<tr>
<th>Location of bone biopsy (n,%)</th>
<th>68Ga-PSMA guided bone biopsies (n= 69)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pelvis</td>
<td>57 82.6%</td>
</tr>
<tr>
<td>Spine</td>
<td>6  8.7%</td>
</tr>
<tr>
<td>Rib</td>
<td>3  4.3%</td>
</tr>
<tr>
<td>Extremity</td>
<td>3  4.3%</td>
</tr>
<tr>
<td>Location of bone biopsy irradiated (n,%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3  4.3%</td>
</tr>
<tr>
<td>Age at biopsy (y) (mean ± SD)</td>
<td>68.5 ± 8.3</td>
</tr>
<tr>
<td>Gleason score at primary diagnosis (n,%)</td>
<td></td>
</tr>
<tr>
<td>&lt;8</td>
<td>22 31.9%</td>
</tr>
<tr>
<td>≥8</td>
<td>39 56.5%</td>
</tr>
<tr>
<td>Unknown</td>
<td>8 11.6%</td>
</tr>
<tr>
<td>Prior local treatment (n,%)</td>
<td></td>
</tr>
<tr>
<td>Radical prostatectomy</td>
<td>15 21.7%</td>
</tr>
<tr>
<td>External radiotherapy prostate</td>
<td>16 32.2%</td>
</tr>
<tr>
<td>Brachytherapy</td>
<td>1  1.4%</td>
</tr>
<tr>
<td>Hormone status at time of biopsy (n,%)</td>
<td></td>
</tr>
<tr>
<td>mHSPC</td>
<td>2  2.9%</td>
</tr>
<tr>
<td>mCRPC</td>
<td>67 97.1%</td>
</tr>
<tr>
<td>Prior second generation ADT (n,%)</td>
<td></td>
</tr>
<tr>
<td>Abiraterone</td>
<td>23 33.3%</td>
</tr>
<tr>
<td>Enzalutamide</td>
<td>34 49.2%</td>
</tr>
<tr>
<td>Prior chemotherapy (n,%)</td>
<td></td>
</tr>
<tr>
<td>Docetaxel</td>
<td>49 71%</td>
</tr>
<tr>
<td>Cabazitaxel</td>
<td>19 27.5%</td>
</tr>
<tr>
<td>Estramustine</td>
<td>1  1.4%</td>
</tr>
<tr>
<td>Prior radiotherapy (n,%)</td>
<td></td>
</tr>
<tr>
<td>Radium-223</td>
<td>5  7.2%</td>
</tr>
<tr>
<td>External radiotherapy metastatic site</td>
<td>21 30.4%</td>
</tr>
<tr>
<td>Laboratory values at time of biopsy (median, range)</td>
<td></td>
</tr>
<tr>
<td>Haemoglobin (mmol/L) (n=67)</td>
<td>8.0 5.3 - 9.5</td>
</tr>
<tr>
<td>Leukocytes (x10^9/L) (n=62)</td>
<td>6.5 3.6 - 13.2</td>
</tr>
<tr>
<td>Thrombocytes (x10^9/L) (n=65)</td>
<td>232 122 - 576</td>
</tr>
<tr>
<td>Alkaline phosphatase (U/L) (n=59)</td>
<td>123 43 - 4598</td>
</tr>
<tr>
<td>LDH (U/L) (n=53)</td>
<td>233 152 - 2718</td>
</tr>
<tr>
<td>PSA (ug/L) (n=63)</td>
<td>96 0.14 - 2375</td>
</tr>
</tbody>
</table>

%; percentage of total number of biopsies with n = 69 biopsies; SD: standard deviation; mHSPC: metastatic hormone sensitive prostate cancer; mCRPC: metastatic castration resistant prostate cancer; ADT: androgen deprivation therapy; LDH: lactate dehydrogenase; PSA: prostate specific antigen.

Table 1 Clinical characteristics at time of biopsy

Sixty-nine 68Ga-PSMA PET guided biopsies from 60 individual patients were included. Seven patients underwent two biopsies during their treatment course. One patient underwent three biopsies during his treatment course.